Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

510.74 +7.82 (+1.55%)
Streaming Delayed Price Updated: 11:37 AM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
58 59 Next >
A Look Into Vertex Pharmaceuticals Inc's Price Over Earnings
Via Benzinga
1 Setback and 1 Opportunity for CRISPR Therapeutics Stock
Despite A bump in the road, the biotech's future looks sunny. 
Via The Motley Fool
2 gene editing stocks to keep on your 2024 watchlist
Gene therapy is receiving much of the spotlight in the medical sector in 2024. The FDA approval for Casgevy, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) 
Via MarketBeat
Exposures Product Safety
Momentum Shifts Back To Tech Stocks As Healthcare Lags In 2024
Small Cap traders are taking a break in 2024 as XBI is down 2.51% YTD. 
Via Talk Markets
A New S&P 500 Bull Market Just Began: 3 No-Brainer Stocks to Buy Hand Over Fist
These stocks seem likely to keep up their winning ways. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Market Whales and Their Recent Bets on VRTX Options
Via Benzinga
The Best Stock to Invest $1,000 in Right Now
This stock has what it takes to be a big winner. 
Via The Motley Fool
Unpacking the Latest Options Trading Trends in Vertex Pharmaceuticals
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Here's How Much $1000 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today
Via Benzinga
If You Invested $10,000 in Vertex Pharmaceuticals in 2018, This Is How Much You Would Have Today
Has investing in Vertex been a better option than just putting your money in the S&P 500? 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Cathie Wood's Flagship ARKK ETF Is Taking On Water Due To Coinbase, Tesla, These Stocks
The flagship ETF's top holdings are down in 2024, especially No. 1 Coinbase. 
Via Investor's Business Daily
Topics ETFs
2 Smart Growth Stocks to Buy Hand Over Fist in 2024
These businesses are on paths to extremely bright futures. 
Via The Motley Fool
3 Unstoppable Growth Stocks That Can Make You Richer in 2024
These big winners of 2023 could keep their momentum going in the new year. 
Via The Motley Fool
These 2 Phenomenal Growth Stocks Can Make You Richer in 2024
One market-beating stock and one beaten-down stock look like tempting buys for very different reasons. 
Via The Motley Fool
3 High-Flying Stocks That Could Soar Even More in 2024
These big winners could keep the momentum going. 
Via The Motley Fool
Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Gene Therapy For Beta-Thalassemia: CRISPR Therapeutics/Vertex's Casgevy Secures FDA Nod Ahead of Schedule
FDA approves CRISPR Therapeutics/Vertex's Casgevy a gene-edited cell therapy for transfusion-dependent beta-thalassemia. Vertex's swift launch strategy targets a network of treatment centers across the... 
Via Benzinga
Exposures Product Safety
Crispr Wins Its Second Gene-Editing Approval In Another Boost To Vertex Stock
Shares of Vertex have risen exponentially since last month. Crispr stock, though, is meandering. 
Via Investor's Business Daily
Vertex Announces US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia
From Vertex Pharmaceuticals Incorporated
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Here's Why CRISPR Therapeutics Stock Rose 54% Last Year
Key regulatory developments sent this biotech stock higher. 
Via The Motley Fool
Down 88%, Could Editas Medicine Be a Good Investment Now?
The past few years have been difficult ones, but shares of the gene editor are far more attractive now that a CRISPR medicine has passed regulatory hurdles. 
Via The Motley Fool
My 3 Highest-Conviction Growth Stocks to Buy in 2024
Simply put, these stocks inspire confidence. 
Via The Motley Fool
3 Growth Stocks to Buy That Could Be Massive Long-Term Winners
These stocks appear to have what it takes to keep up their winning ways. 
Via The Motley Fool
3 Unstoppable Stocks to Buy in 2024
These stocks appear to be on a clear path to continued growth. 
Via The Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Bought This Week
These companies could stand out thanks to game-changing technology. 
Via The Motley Fool
Uber, Abbott Laboratories, Vertex Pharmaceuticals And More On CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management said Uber Technologies, Inc. (NYSE: UBER) shares hit an all-time high on Thursda 
Via Benzinga
3 Stocks to Buy in the Booming Field of Gene Editing
As the promise of gene editing moves closer to being a reality, these gene editing stocks have the opportunity for long-term gains. 
Via InvestorPlace
Should Quality-Oriented Investors Explore VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX)?
Reasonable growth and debt and a high ROIC for VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX). 
Via Chartmill
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
58 59 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.